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Abstract
Remission is the primary goal of treatment for major depressive disorder (MDD). However, some patients do not respond to
treatment. The main purpose of this study was to determine whether brain-derived neurotrophic factor (BDNF) levels are
correlated with treatment outcomes. In a naturalistic study, we assessed whether plasma BDNF levels were correlated with
clinical outcomes by measuring plasma BDNF in patients with depressive syndrome (MADRS score $18), and subsequently
comparing levels between the subgroup of patients who underwent remission (MADRS score #8) and the subgroup who
were refractory to treatment (non-responders). Patients with depressive syndrome who underwent remission had
significantly higher plasma BDNF levels (p,0.001), regardless of age or sex. We also found a significant negative correlation
between MADRS scores and plasma BDNF levels within this group (r=–0.287, p=0.003). In contrast, non-responders had
significantly lower plasma BDNF levels (p=0.029). Interestingly, plasma BDNF levels in the non-responder group were
significantly higher than those in the remission group in the initial stage of depressive syndrome (p=0.002). Our results
show that plasma BDNF levels are associated with clinical outcomes during the treatment of depression. We suggest that
plasma BDNF could potentially serve as a prognostic biomarker for depression, predicting clinical outcome.
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Introduction
Remission is defined in The Diagnostic and Statistical Manual
(DSM-IV) as the absence of significant signs or symptoms, and is
the primary goal of treatment for major depressive disorder
(MDD). At present, the category of depression (e.g., severe,
moderate, mild or remission) is primarily evaluated by the patient
using various subjective indices; however, there is currently no
biomarker that could serve as an objective index for evaluating the
severity or progression of MDD.
Brain-derived neurotrophic factor (BDNF) has increasingly
attracted attention among researchers investigating MDD, as
numerous reports have indicated that it plays an important role in
the illness [1]. BDNF is a member of the neurotrophin family and
plays a critical role in the survival, differentiation and outgrowth of
peripheral and central neurons during development and in
adulthood [2,3].
Serum and plasma levels of BDNF are decreased in patients
suffering from MDD [4,5,6,7,8]. In addition, serum BDNF levels
are correlated with the severity of depression [9], and serum
BDNF levels in patients treated with antidepressants increase to
levels found in healthy subjects [8,10,11]. Moreover, BDNF levels
in the hippocampus and prefrontal cortex are significantly reduced
in suicide victims compared with non-suicide controls [12].
Although most studies to date have shown that serum BDNF
levels increase with antidepressant treatment, the usefulness of
serum BDNF as a biomarker for MDD is not yet clear.
Among MDD patients, there exist two distinct groups: a group
that responds to treatment (the responder group) and a group that
is refractory to treatment (the non-responder group). To our
knowledge, no study to date has examined plasma BDNF levels in
non-responder MDD patients.
The majority of studies that have examined depression have
been prospective studies. Our report describes the first naturalistic
study examining BDNF levels in remission and non-responder
groups. To better understand the role of BDNF in MDD, we
compared the changes in plasma BDNF levels in remission and
non-responder groups of patients with depressive syndrome.
Methods
Depression Assessment
The Montgomery-A ˚sberg Depression Rating Scale (MADRS)
[13] is increasingly employed in clinical research since results from
earlier studies had suggested that the scale could be superior to the
traditional HAMD17 with respect to sensitivity to change
[13,14,15] and other psychometric properties [16]. The severity
of depression was assessed using the MADRS every two weeks by
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39212
          Registration:independent experienced raters. The raters were objective and
were not concerned with treatment outcome. We used a MADRS
score #18 points to separate symptoms more than moderate from
symptoms mild depression [17]. We used MADRS scores to
identify patients with depressive syndrome (defined as MADRS of
at least 18 points), and to differentiate between non-responders
(defined as those showing a ,50% reduction in MADRS score
from the depressive symptom stage) and patients in remission
(defined as those with a MADRS score #8 after treatment [17]).
The period from the depressive syndrome stage to the response
stage was 7.268.6 weeks, and the period from the depressive
syndrome stage to the remission stage was 12.3612.6 weeks. To
investigate differences between the remission and the non-
responder groups, we examined different time periods during
the course of treatment. The treatment period selected for the
non-responder group was closely matched with that of the
remission group and was determined to be an 8-week period.
Furthermore, the period-matched depressive symptom-remission
time frame was determined to be 12 weeks in the non-responder
group.
Subjects
A detailed flow chart of patient selection and grouping during
the study is shown in Fig. 1. The subjects were recruited from a
total of 110 MDD patients admitted to the in- and out-patient
clinics of Sato Hospital, Koutokukai, between June 2006 and
March 2009. All patients were suffering from a current major
depressive episode–single episode [DSM-IV-TR codes: 296.2] or
recurrent episodes [DSM-IV-TR codes: 296.3]–diagnosed accord-
ing to the Diagnostic and Statistical Manual for Mental Disorders,
fourth edition, text version (DSM-IV-TR, American Psychiatric
Association, 2000). Subjects with any other diagnosed mental or
severe physical illness were excluded from the study. After the
procedures were fully explained, all participants gave informed
consent. Written informed consent was obtained from all patients
participating in the study and the study protocols were approved
by the Ethics Committee of Sato Hospital, Koutokukai and the
Ethics Committee of Graduate School of Pharmaceutical Sciences,
Tohoku University, and was standard procedure in clinical trials
involving vulnerable participants in the Japan. This study was
performed according to the ethical standards of the Declaration of
Helsinki. Also, written informed consent was obtained from the
participants, and their parents (guardians) if the participants were
children. All participants who declined to participate or otherwise
did not participate were eligible for treatment and were not
disadvantaged in any other way by not participating in the study.
As a criterion for inclusion of patients in this study, we chose a
MADRS score $18 points (symptoms more than moderate).
Thus, from a total of 110 patients, 79 were selected for inclusion in
the study. We then categorized these patients into two groups: a
remission group (patients experiencing an improvement of
symptoms; MADRS scores #8 after treatment) and a non-
responder group (patients refractory to treatment, showing a
,50% reduction in MADRS score). The final analysis included 48
Figure 1. Diagram showing the selection of subjects during the study.
doi:10.1371/journal.pone.0039212.g001
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women; average age 44.3618.6 years, range 17–87 years), and 10
subjects in the non-responder group (three men and seven women;
average age 50.4615.2 years, range 18–71 years). Subjects were
dividedintotwo groups based oneither sexor medianage(43.9 years)
to investigate whether these factors affected plasma BDNF. Thirty-
one patients were excluded because they either ceased treatment
within three months (n=24), received intermittent treatment (n=5),
or showed response with incomplete remission (n=2).
None of the subjects was taking hormone therapies (including
oral contraceptives). Most patients (47/48 patients) had been
prescribed antidepressants by psychiatrists. Psychiatrists treated
patients with homogeneous psychotherapy. The following antide-
pressant drugs were administered to the remission group in the
depressive syndrome stage: amitriptyline (50–150 mg/day; n=2),
clomipramine (30–150 mg/day; n=4), fluvoxamine (25–150 mg/
day; n=11), imipramine (75 mg/day; n=1), maprotiline (75 mg/
day; n=1), milnacipran (50–200 mg/day; n=8), paroxetine
(10 mg/day; n=3), sertraline (25–100 mg/day; n=8), sulpiride
(150–300 mg/day; n=6) and trazodone (25–100 mg/day; n=4).
The non-responder group received the following antidepressant
drugs in the depressive syndrome stage: amoxapine (125 mg/day;
n=1), aripiprazole (3 mg/day; n=1), fluvoxamine (125 mg/day;
n=1), maprotiline (25 mg/day; n=2), milnacipran (150 mg/day;
n=1), paroxetine (10–40 mg/day; n=5), sertraline (25–100 mg/
day; n=2), sulpiride (300 mg/day; n=1) and trazodone (50 mg/
day; n=1). The following antidepressant drugs were administered
to the remission group in the response stage: amitriptyline (50–
150 mg/day; n=3), aripiprazole (3 mg/day; n=1), clomipramine
(50–75 mg/day; n=5), fluvoxamine (50–150 mg/day; n=9),
imipramine (150 mg/day; n=1), maprotiline (50–75 mg/day;
n=3), milnacipran (50–150 mg/day; n=8), paroxetine (10–
30 mg/day; n=3), sertraline (25–100 mg/day; n=9), sulpiride
(50–300 mg/day; n=7) and trazodone (25–100 mg/day; n=3).
The non-responder group received the following antidepressant
drugs at the 8-week period: amitriptyline (25 mg/day; n=1),
amoxapine (175 mg/day; n=1), aripiprazole (18 mg/day; n=1),
clomipramine (105 mg/day; n=1), hange-kobuku-to (a Chinese
herbal medicine; 7.5 g/day; n=1), imipramine (30 mg/day;
n=1), maprotiline (75 mg/day; n=1), milnacipran (50–60 mg/
day; n=3), paroxetine (20–40 mg/day; n=4), sertraline (25 mg/
day; n=1), sulpiride (300 mg/day; n=1) and trazodone (50 mg/
day; n=1). The following antidepressant drugs were administered
to the remission group in the remission stage: amitriptyline (50–
150 mg/day; n=3), aripiprazole (6 mg/day; n=1), clomipramine
(50–100 mg/day; n=7), fluvoxamine (50–150 mg/day; n=7),
imipramine (250 mg/day; n=1), maprotiline (75–100 mg/day;
n=2), milnacipran (50–200 mg/day; n=8), paroxetine (10–
30 mg/day; n=4), sertraline (25–100 mg/day; n=9), sulpiride
(150–300 mg/day; n=5) and trazodone (25–100 mg/day; n=3).
Meanwhile, the non-responder group received the following
antidepressant drugs during the 12-week period: amitriptyline
(25 mg/day; n=1), amoxapine (100–175 mg/day; n=3), aripi-
prazole (15 mg/day; n=1), clomipramine (25–225 mg/day;
n=2), hange-kobuku-to (7.5 g/day; n=1), maprotiline (75 mg/
day; n=1), milnacipran (50–180 mg/day; n=3), paroxetine (20–
40 mg/day; n=2), sertraline (25 mg/day; n=1) and trazodone
(50 mg/day; n=1). Although one subject underwent modified
electroconvulsive therapy (weeks 36–41), the patient did not
achieve a response. In one patient, the side effects of the
antidepressants were considered too adverse; therefore, the patient
asked to receive Chinese medicine rather than antidepressants.
There was no bias in treatments with SSRIs, SNRIs, TCA and
tetracyclic antidepressants between the remission and non-
responder groups within the depressive syndrome stage and at
the end point (Chi-square test, p.0.05).
Sample Collection
Blood was withdrawn from each subject by venipuncture into a
blood collection tube containing EDTA as an anticoagulant
between 10:00 and 17:00. The tubes were immediately cooled to
4uC and then centrifuged at 20006g for 20 min. Plasma was kept
frozen at –80uC until assayed.
BDNF Assay
Plasma BDNF levels were measured using an ELISA kit (BDNF
Emax Immunoassay System, Promega, Madison, WI, USA) after
appropriate dilution of samples (1:10 to 1:50) in blocking and
sample buffer according to the manufacturer’s instructions. The
BDNF standard provided with this system was used to generate a
standard curve that was linear between 3.9 and 500 pg/ml. Beyond
these limits, BDNF concentrations could not be accurately
extrapolated from the standard curve. Therefore, to determine
BDNF concentrations in the diluted samples, we used only values
that were within the linear range of this standard curve. Briefly, 96-
well flat-bottom immunoplates were coated with anti-BDNF
monoclonal antibody (mAb) and incubated at 4uC for 18 h. Plates
were washed with Tris-buffered saline containing 0.1% Tween 20,
pH 7.6 (TBS-T). After blocking non-specific binding with blocking
and sample buffer for 1 h at room temperature (RT), standards and
samples were added to the plates, incubated on a shaker for 2 h at
RT, and then washed with TBS-T. The plates were subsequently
incubated with anti-human BDNF polyclonal antibody at RT for 2
hours, washed, and incubated with anti-IgY antibody conjugated to
horseradish peroxidase for 1 hour at RT, followed by washing with
TBS-T. Tetramethyl-benzidine was then added to produce the
color reaction. After stopping the reaction with 1 N HCl, the
absorbance was read at 450 nm on a Sunrise Classic microplate
reader (Tecan, Mannedolf, Switzerland) and BDNF concentrations
were determined automatically according to the BDNF standard
curve (ranging from 7.8 to 500 pg/ml of BDNF). Measurements
were performed in duplicate.
Data Analysis
Statistical analyses of MADRS scores and plasma BDNF levels
were performed using one-way repeated measures analysis of
variance (rep-ANOVA) with three levels of symptoms or periods.
Post-hoc tests were performed on ANOVA results using the
Bonferroni correction for multiple comparisons. Between-group
comparisons wereperformed using unpaired, two-tailed Student’s t-
tests. Data are shown as the means 6 standard deviation (mean 6
S.D.). Correlation analysis was performed using Spearman’s
correlation. Statistical significance was defined as p,0.05. Normal-
ity testing was performed using the Shapiro-Wilk test. Possible
violations of the sphericity assumption were assessed by Mauchly’s
test. Analyses were performed using SPSS software version 16.0.
Results
Characteristics of MDD Patients
The subjects’ characteristics are summarized in Table 1. No
significant differences were found between the remission and non-
responder groups in terms of gender, age or MADRS score in the
depressive syndrome stage.
Remission Group
Remission group patients were defined as those with a MADRS
score #8, reducing from a score of at least 18 points, after
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response and remission after treatment were 33.768.9, 10.965.9,
and 5.062.4, respectively. Patients in the remission group had
significantly reduced MADRS scores during the treatment (repeat-
ed-measures ANOVA; F1, 37=344.017, p,0.001). There were
significant differences in MADRS scores among stages within the
remission group (depressive symptoms vs response (p,0.001),
depressive symptoms vs remission (p,0.001), and response vs
remission (p,0.001); Bonferroni’s multiple comparison).
The period from the depressive syndrome stage to the response
stage was 7.268.6 weeks, and the period from the depressive
syndrome stage to the remission stage was 12.3612.6 weeks.
Plasma BDNF levels in the depressive syndrome, response and
remission stages in the remission group were 1 82761 340,
2 40261 610, and 3 15862 033 pg/ml, respectively. Patients in
the remission group had significantly higher plasma BDNF levels
at remission than in the depressive syndrome and response stages
(repeated-measures ANOVA; F1, 37=25.083, p,0.001) (Fig.2).
Plasma BDNF levels differed significantly among stages within the
remission group (depressive symptoms vs response (p=0.004);
depressive symptoms vs remission (p,0.001); and response vs
remission (p=0.003); post hoc ANOVA Bonferroni’s Multiple
Comparison).
Treatment of the remission group led to an expected decrease in
MADRS scores, and this was accompanied by a significant
increase in plasma BDNF levels. Correspondingly, we found a
significant negative correlation between MADRS scores and
plasma BDNF levels within the remission group (r=–0.287,
p=0.003, n=114) (Fig.3).
Non-responder Group
To investigate differences between the remission and the non-
responder groups, we examined different time periods during the
course of treatment.
The MADRS scores in the non-responder group at the
depressive syndrome stage, and at 8 and 12 weeks after the
commencement of treatment were 35.166.5, 25.867.7, and
35.2611.4, respectively. Patients in the non-responder group
exhibited no significant change in MADRS score between 8 and
12 weeks (repeated-measures ANOVA; F1, 9=0.001, p=0.982).
Plasma BDNF levels in the non-responder group at the
depressive syndrome stage, and at 8 and 12 weeks after the
Table 1. Initial Characteristics of Remission and Non-responder groups among MDD patients.
Remission group Non-responder group p-value
(n=38) (n=10)
Gender (M/F) 19/19 3/7 0.259
a
Mean age (S.D.) 44.3 (18.6) 50.4 (15.2) 0.178
b
Mean MADRS score (S.D.) 33.7 (8.9) 35.1 (6.5) 0.454
b
Mean plasma BDNF (S.D.) (pg/mL) 1827 (1340) 2932 (2373) 0.002
b
MADRS, Montgomery-A ˚sberg Depression Rating Scale; BDNF, brain-derived neurotrophic factor.
aChi square test.
bStudent’s t-test.
doi:10.1371/journal.pone.0039212.t001
Figure 2. Changes in plasma BDNF levels in MDD patients (remission [&, n=38] and non-responder [%, n=10] groups). The period-
matched symptom-response and symptom-remission outcomes were examined at 8 and 12 weeks, respectively, in the non-responder group. Plasma
BDNF levels were measured by immunoassay. Each point represents the mean. The statistical significance of differences was calculated using
repeated-measures ANOVA with post-hoc Bonferroni testing (*p,0.05). The statistical significance of differences in plasma BDNF levels between
remission (&) and non-responder (%) groups at the depressive syndrome stage were calculated using the Students’ t-test (
#p,0.05).
doi:10.1371/journal.pone.0039212.g002
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and 1 61961 698 pg/ml, respectively. Interestingly, patients in the
non-responder group showed significantly reduced plasma BDNF
levels between weeks 8 and 12 (repeated-measures ANOVA;
F1, 9=6.743, p=0.029) (Fig.2). Surprisingly, treatment of the non-
responder group produced no change in MADRS score by 12
weeks, although these patients did show a significant decrease in
plasma BDNF levels. We found no significant correlation between
MADRS scores and plasma BDNF levels (r=–0.112, p=0.554,
n=30) in the non-responder group.
Comparison of the Remission and Non-responder Groups
at the Depressive Syndrome Stage
To determine whether plasma BDNF levels could predict
treatment outcome, we examined plasma BDNF levels in the
remission and non-responder groups at the initial depressive
syndrome stage. Surprisingly, the non-responder group had higher
plasma BDNF levels compared with the remission group
(p=0.002) (Fig.2).
No Effect of Sex or Age on Plasma BDNF
We next investigated whether sex and/or age affected plasma
BDNF. We divided the subjects into two groups based on either sex
or median age (43.9 years). The results for the remission group are
summarizedinTable2.PlasmaBDNFwasnotaffectedbysexorage.
Discussion
To gain insight into the different outcomes during the course of
treatment for depression, we examined whether plasma BDNF
levels underwent a change at different stages (syndrome, response
and remission) and the equivalent time points in non-responders,
focusing on differences between remission and non-responder
groups. In the remission group, plasma BDNF levels increased
significantly with clinical improvement, independent of sex and
age.
Although options for pharmacologic treatment have expanded
significantly in the past 20 years, between one- and two-thirds of
patients do not respond to the first antidepressant prescribed, and
15–33% do not respond to multiple interventions [18]. In this
study, the non-responder group comprised 21% (10/48) of the
study population, consistent with the above report. However, the
resultant difference in the numbers of patients in the remission
(79% (38/48)) and non-responder groups (21% (10/48)) is a
limitation of a naturalistic study such as ours.
Of note, we show for the first time that patients in the non-
responder group have significantly decreased plasma BDNF levels
during the syndrome’s 8–12 week period. Thus, plasma BDNF
may serve as an important biomarker for the prognosis of MDD.
In this study, we focused on remission. An advantage of a
naturalistic study such as ours is that we could compare plasma
BDNF as a biomarker between patients achieving remission and
non-responders. For the purposes of comparison, we observed
scores in non-responders at the corresponding time points to those
at which patients in the remission achieved a response and
remission. However, the disagreement of the period of remission
and the period examined in non-responders (despite each stage
being matched) is a limitation of naturalistic studies. Another
limitation is the potential variation in drug treatment between the
two groups of depressed patients. The effects of antidepressants on
peripheral BDNF levels are not uniform [19,20]. Thus, although
most studies to date have shown that serum BDNF levels increase
with antidepressant treatment, different classes of antidepressants-
induced changes in BDNF in the peripheral blood are not always
uniform. However, in the present naturalistic study, there was no
major bias in drug treatment between the remission and non-
responder groups. There was no bias in treatments with SSRIs,
SNRIs, TCA and tetracyclic antidepressants between the remis-
sion and non-responder groups within the depressive syndrome
stage and at the end point (Chi-square test, p.0.05). Also, some
patients were treated with multiple antidepressants.
Individual differences in plasma BDNF levels were large, and
consequently, plasma BDNF levels may have differed between
groups. Therefore, although plasma BDNF may be a valuable
biomarker for the treatment of depression, it may not be
appropriate or feasible to establish a normal range (as is done
Figure 3. Correlation of plasma BDNF levels and MADRS scores in the remission group (n=38*, 3 states). There was a significant
negative correlation between plasma BDNF levels and MADRS scores (r=–0.287, p=0.003). Statistical analysis was performed using Spearman’s
correlation test.
doi:10.1371/journal.pone.0039212.g003
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assessing physiological status). Thus, it is necessary to measure
plasma BDNF regularly in each MDD patient, and a careful
examination of the BDNF profile, to examine trends or shifts, is
necessary for the clinician to select an appropriate treatment.
Plasma BDNF levels decreased during the course of treatment
in the non-responder group. BDNF levels are increased by not
only antidepressants, but also by environmental enrichment [21]
and modest exercise [22]. In contrast, BDNF levels are decreased
by stressful events. Plasma BDNF levels were decreased in non-
responders treated with antidepressants suggesting that the ability
of stress to decrease BDNF levels may be greater than the ability of
antidepressants to increase BDNF levels.
Notably, we found that plasma BDNF concentrations were
significantly different between the remission and non-responder
groups at the depressive syndrome stage. This important
observation suggests that the biological backgrounds of patients
with treatment-responsive MDD and patients with treatment-
resistant MDD might differ, and that high plasma BDNF levels
during the depressive syndrome stage may be indicative of
treatment-resistant MDD patients. Thus, plasma BDNF levels
may help the clinician to predict clinical outcome. In particular, if
plasma BDNF levels decrease or are unchanged in an individual
with regularly measured plasma BDNF, the clinician may need to
reevaluate treatment strategy.
In 2002, the involvement of serum BDNF in stress and major
depression was reported for the first time [5]. Over the last 14
years, most studies have examined serum BDNF rather than
plasma BDNF [23]. However, Piccinni et al suggested that plasma
BDNF may be more appropriate as a biomarker of physiological
status, while serum BDNF is more likely to represent a trait marker
[7]. Very recently, plasma BDNF was associated with response in
the early course of treatment for depression [24].
In our study, plasma BDNF levels in patients in the remission
group significantly increased during the transition from syndrome
to response to remission stages, suggesting that plasma BDNF may
be a useful marker of physiological status and that it should be
examined in patients on a regular basis.
A correlation between cortical BDNF and serum BDNF in
young rats was first shown by Karege et al. [5]. In contrast, Elfving
et al. found a negative correlation between hippocampal and
serum BDNF levels [25]. In blood, BDNF is mainly stored in
thrombocytes, with only a minor free fraction present in plasma
[26]. Recently, plasma BDNF levels were shown to be positively
correlated with hippocampal BDNF levels [27]. The origin of
plasma BDNF is not entirely clear, although it appears that the
hippocampus is the main source.
Brain imaging studies have documented a reduction in
hippocampal volume in depressed subjects [28], which can be
attenuated [29], or even improve [30] with antidepressant
treatment. These observations suggest that plasma BDNF may
be involved in the pathophysiology of MDD. Thus, we posit that
increased plasma BDNF may have a therapeutic effect on the
hippocampus.
Six of the 38 patients (16%) in the remission group exhibited a
reduction in plasma BDNF levels. One possible explanation for
this is that, although depression was diagnosed according to DSM-
IV-TR, differences in biological backgrounds may generate
different subgroups within the remission group. Another possibility
is that an improvement in depressive symptoms may be directly
Table 2. MDD Remission group characteristics by sex and age, and Non-responder group characteristics.
Syndrome Response Remission F p-value
a
Total Remission
(n=38) MADRS (S.D.) 33.7 (8.9) 10.9 (5.9) 5 (2.4) 334 ,0.001
BDNF (S.D.) 1827 (1340) 2402 (1610) 3158 (2033) 25.1 ,0.001
Male Remission (mean age, 36.9 (14.0)
b)
(n=19) MADRS (S.D.) 33.1 (8.9) 11.2 (6.2) 5 (2.3) 155.3 ,0.001
BDNF (S.D.) 1811 (1309) 2239 (1173) 2994 (2042) 8.85 0.008
Female Remission (mean age, 51.7 (19.9)
b)
(n=19) MADRS (S.D.) 34.3 (9.1) 10.7 (5.9) 5.1 (2.6) 181.9 ,0.001
BDNF (S.D.) 1843 (1405) 2565 (1973) 3321 (2067) 16.87 0.001
Young Remission (median age ,43.9; mean age, 28.7 (6.9))
(n=19) MADRS (S.D.) 34.6 (8.7) 12.6 (6.6) 5.5 (2.1) 180.5 ,0.001
BDNF (S.D.) 1428 (1163) 1995 (1210) 2582 (1419) 10.89 0.004
Old Remission (median age $43.9; mean age, 60.0 (12.0))
(n=19) MADRS (S.D.) 32.7 (9.2) 9.3 (4.8) 4.6 (2.7) 156.2 ,0.001
BDNF (S.D.) 225.8 (1414) 2810 (1873) 3733 (2405) 13.82 0.002
Syndrome 8 weeks 12 weeks F p-value
a
Non-responder
(n=10) MADRS (S.D.) 35.1 (6.5) 25.8 (7.7) 35.2 (11.4) 0.001 0.982
BDNF (S.D.) 2932 (2373) 2117 (2042) 1619 (1698) 6.743 0.029
MADRS, Montgomery-A ˚sberg Depression Rating Scale; BDNF, brain-derived neurotrophic factor.
aone-way repeated measures analysis of variance.
bsignificant difference between male and female ages by Student’s t-test.
doi:10.1371/journal.pone.0039212.t002
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antidepressant, although this hypothesis needs to be examined.
These findings suggest that plasma BDNF levels are likely to be a
biomarker for MDD, and that the onset and improvement of the
disease might be associated with changes in plasma BDNF levels
elicited by antidepressant treatment.
Insummary,the present studyshowsthat plasmaBDNFlevelsare
positively correlated with clinical improvement in patients who
undergo remission,and that patientswho are refractory to treatment
have higher plasma BDNF levels than patients who achieve
remission at the initial depressive syndrome stage. Therefore, it is
very likely that plasma BDNF levelsplayan important role inMDD.
Our naturalistic preliminary study reveals that plasma BDNF could
represent a useful biomarker for predicting clinical outcome during
the course of treatment for MDD.
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